The inhibitory effect of M2 macrophage-derived exosomes on gefitinib resistant lung adenocarcinoma cells through the MIF/TIMP1/CD74 axis by Jingcui Peng, Yan Zhang, Bin Li, Xin He, Cuimin Ding, Wenxia Hu

Get full text

Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis by Xinyue Wang, Zhaona Li, Liuchun Wang, Yan Liang, Chun Huang, Peng Chen, Dingzhi Huang, Xia Song, Cuimin Ding, Changli Wang, Richeng Jiang

Get full text

Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial by Tianqing Chu, Hua Zhong, Zhuang Yu, Jing Wang, Yanqiu Zhao, Xiaoqian Mu, Xinmin Yu, Xun Shi, Qingming Shi, Maojing Guan, Cuimin Ding, Nan Geng, Jialin Qian, Baohui Han

Get full text

Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A... by Yuequan Shi, Xiaoyan Liu, Anwen Liu, Jian Fang, Qingwei Meng, Cuimin Ding, Bin Ai, Yangchun Gu, Cuiying Zhang, Chengzhi Zhou, Yan Wang, Yongjie Shui, Siyuan Yu, Dongming Zhang, Jia Liu, Haoran Zhang, Qing Zhou, Xiaoxing Gao, Minjiang Chen, Jing Zhao, Wei Zhong, Yan Xu, Mengzhao Wang, Xiangxiang Pan

Get full text

Efficacy and safety of bevacizumab biosimilar SIBP04 compared with bevacizumab (Avastin®) as first-line treatment for locally advanced or metastatic non-squamous non-small-cell lun... by Yuankai Shi, Minghong Bi, Qingshan Li, Guolei Wang, Jianhua Chen, Mingjun Li, Jianhua Shi, Jiazhuan Mei, Yinghua Ji, Qingdi Xia, Yuanqing Feng, Shufeng Xu, Tongmei Zhang, Xiaohui Gao, Shubin Tang, Jie Weng, Zhuo Cao, Hongbo Wu, Xiubao Ren, Hua Xie, Hua Liu, Qiang Liu, Xing Yin, Xiaoyong Luo, Jun Chen, Haiming Zhang, Zhiyuan Guo, Cuimin Ding, Xin Jin, Rongli Sun, Sheng Yang

Get full text